Personal information

Websites & social links

LinkedIn

Other IDs

Scopus Author ID: 25930352200

Activities

Collapse all

Employment (1)

KalVista Pharmaceuticals: Porton Down, Wiltshire, GB

2011-05 to present | Vice President, Research
Employment
Source: Self-asserted source
Sally L Hampton

Works (7)

Discovery of α-Amidobenzylboronates as Highly Potent Covalent Inhibitors of Plasma Kallikrein

ACS Medicinal Chemistry Letters
2024-04-11 | Journal article
DOI: 10.1021/acsmedchemlett.3c00572
Contributors: Matthew Allison; Rebecca L. Davie; Adrian J. Mogg; Sally L. Hampton; Jonas Emsley; Michael J. Stocks
Source: check_circle
Crossref

Sebetralstat: A Rapidly Acting Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema

Drugs and Drug Candidates
2024-04-07 | Journal article
DOI: 10.3390/ddc3020019
Contributors: Edward P. Feener; Rebecca L. Davie; Nivetha Murugesan; Stephen J. Pethen; Sally L. Hampton; Michael D. Smith; Paul K. Audhya; Chris M. Yea
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema.

Journal of medicinal chemistry
2022-10-17 | Journal article
DOI: 10.1021/acs.jmedchem.2c00921
PMID: 36251573
PMC: PMC9620001
Contributors: Sally L Hampton; Rebecca Louise Davie; Edwards HJ; Evans DM; Hodgson ST; Michael Stocks; Smith AJ; Rushbrooke LJ; Pethen SJ; Michael Roe et al.
Source: Self-asserted source
Sally L Hampton

Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on‐demand treatment of hereditary angioedema

Clinical & Experimental Allergy
2022-09 | Journal article
DOI: 10.1111/cea.14122
Contributors: Edward J. Duckworth; Nivetha Murugesan; Lily Li; Louise J. Rushbrooke; Daniel K. Lee; Gian Marco De Donatis; Andreas Maetzel; Christopher M. Yea; Sally L. Hampton; Edward P. Feener
Source: check_circle
Crossref

KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results.

The Journal of allergy and clinical immunology
2022-01-24 | Journal article
DOI: 10.1016/j.jaci.2021.10.038
PMID: 35086692
Contributors: Sally L Hampton; Maetzel A; Smith MD; Duckworth EJ; Hampton SL; De Donatis GM; Murugesan N; Rushbrooke LJ; Li L; Francombe D et al.
Source: Self-asserted source
Sally L Hampton

Genetic interventions in mammalian cells; Applications and uses in high-throughput screening and drug discovery

Cell Biology and Toxicology
2010 | Journal article
DOI: 10.1007/s10565-009-9140-z
EID:

2-s2.0-76749161255

Part of ISSN: 07422091
Contributors: Hampton, S.L.; Kinnaird, A.I.
Source: Self-asserted source
Sally L Hampton via Scopus - Elsevier

New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists

Journal of Medicinal Chemistry
2008 | Journal article
DOI: 10.1021/jm8008162
EID:

2-s2.0-58149093623

Part of ISSN: 00222623
Contributors: Yea, C.M.; Allan, C.E.; Ashworth, D.M.; Barnett, J.; Baxter, A.J.; Broadbridge, J.D.; Franklin, R.J.; Hampton, S.L.; Hudson, P.; Horton, J.A. et al.
Source: Self-asserted source
Sally L Hampton via Scopus - Elsevier
How many people are using ORCID?